Together, these data emphasize the potential of these two compounds in alleviating cognitive-behavioral deficits associated with AD and identifies c-KIT inhibition as a putative method for therapeutic intervention when treating neurodegenerative disorders. This evidence concerns the gene KIT and Alzheimer disease.